Frank J. Quintero Joins BioSig Technologies Advisory Board
Santa Monica, CA, April 09, 2019 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that Frank J. Quintero, a Los Angeles-based investor, joined the Advisory Board of the Company.
Mr. Quintero is a Principal at The Yucaipa Companies, a premier investment firm founded by Ron Burkle in 1986. His responsibilities as a Principal of the firm encompass deal origination, negotiating transactions, investor relations and corporate communications. Working closely with The Yucaipa Companies' founder, Mr. Quintero actively participated in multiple phases of the investment process since joining the firm. The Yucaipa Companies has completed mergers and acquisitions valued at more than $35 billion.
Prior to joining The Yucaipa Companies, Mr. Quintero served as Special Assistant to California Governor Gray Davis. In this position he served as a liaison to labor officials and business groups; as well as local, state, and national elected officials. Mr. Quintero was also an advisor to Governor Davis on over 300 boards and commission appointments within the California state government. Under Governor Davis' leadership the Appointments Unit placed more women and people of color in appointed positions than any of California's previous governors.
Active in numerous statewide and local political campaigns, in 1998 Mr. Quintero worked as State Field Director for the California Democratic Party Coordinated Campaign. As part of the three-person team managing a budget of several million dollars, Mr. Quintero directed over thirty offices throughout the state and oversaw print, radio, and direct mail advertising. His efforts on behalf of the Coordinated Campaign's “Get-Out-The-Vote” drive produced record voter registration and turnout in low-income communities.
Based on his experience unifying divergent groups, Mr. Quintero was chosen as one of 60 Americans to receive a Marshall Fellowship in 2001. He became part of a team of scholars and government officials brought together to advise European Union member nations, NGOs, and the head of NATO on economic integration and immigration policy.
“Frank brings to us very impressive track record in investment, government and communications sectors. We are confident that Frank’s many achievements and his strong relationships in the state of California will be a definite advantage to our growing operations, ” commented Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc.
The goal of the Advisory Board is to advise the leadership of BioSig on a range of subjects, including financing, strategy, marketing, government affairs, partnerships and M&A. Current Members of the Board include Los Angeles-based political advisor and business leader Mr. Sim Farar, San Francisco Bay area based Mr. Kent Bennett Williams, CEO and Principal at Vista Asset Management, LLC, Texas-based Dr. Ramachandra Malya, Medical Director, and Los Angeles based investor, recording artist and a songwriter D.A. Wallach.
“I have been impressed by BioSig’s innovative thinking and their dedication to advance medicine through novel technological solutions. I look forward to working with the management and contribute my expertise to enhance the Company’s growth,” commented Mr. Quintero.
About BioSig Technologies
BioSig Technologies is a medical technology company developing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace (www.biosig.com). Led by a proven management team and a veteran, independent Board of Directors, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The technology has been developed to address an unmet need in a large and growing market.
The Company’s first product, PURE EP™ System, is a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision-making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. BioSig has partnered with Minnetronix on technology development and received FDA 510(k) clearance for the PURE EP™ System in August 2018.
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Natasha Drapeau BioSig Technologies, Inc. Executive Vice President 12424 Wilshire Blvd, Ste 745 Los Angeles, CA 90025 firstname.lastname@example.org 310-620-9320
Released April 9, 2019